Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE
Matthew Roberts,
Julia Ogden,
AS Mukarram Hossain,
Anshuman Chaturvedi,
Alastair RW Kerr,
Caroline Dive,
Jennifer Ellen Beane,
Carlos Lopez-Garcia
Affiliations
Matthew Roberts
Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom
Julia Ogden
Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom; Translational Lung Cancer Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Macclesfield, United Kingdom
AS Mukarram Hossain
Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom
Anshuman Chaturvedi
Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom; Department of Histopathology, The Christie Hospital, Manchester, United Kingdom
Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom
Caroline Dive
Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, Macclesfield, United Kingdom; Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom
Jennifer Ellen Beane
Boston University School of Medicine, Boston, United States
Cancer Research UK Lung Cancer Centre of Excellence, Alderley Park, United Kingdom; Translational Lung Cancer Biology Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Macclesfield, United Kingdom
Lung squamous cell carcinoma (LUSC) is a type of lung cancer with a dismal prognosis that lacks adequate therapies and actionable targets. This disease is characterized by a sequence of low- and high-grade preinvasive stages with increasing probability of malignant progression. Increasing our knowledge about the biology of these premalignant lesions (PMLs) is necessary to design new methods of early detection and prevention, and to identify the molecular processes that are key for malignant progression. To facilitate this research, we have designed XTABLE (Exploring Transcriptomes of Bronchial Lesions), an open-source application that integrates the most extensive transcriptomic databases of PMLs published so far. With this tool, users can stratify samples using multiple parameters and interrogate PML biology in multiple manners, such as two- and multiple-group comparisons, interrogation of genes of interests, and transcriptional signatures. Using XTABLE, we have carried out a comparative study of the potential role of chromosomal instability scores as biomarkers of PML progression and mapped the onset of the most relevant LUSC pathways to the sequence of LUSC developmental stages. XTABLE will critically facilitate new research for the identification of early detection biomarkers and acquire a better understanding of the LUSC precancerous stages.